Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Ajai Chari, MD, Mount Sinai Hospital
Advertisement
Articles by Ajai Chari, MD, Mount Sinai Hospital
Advertisement
Latest Updated Articles
Updates in Multiple Myeloma in the Frontline SettingPublished: January 29th 2021 | Updated:
Updates in Relapsed/Refractory MyelomaPublished: January 29th 2021 | Updated:
Third and Subsequent Line Options for Multiple MyelomaPublished: January 29th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5